AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy

After the approval of their partnered anti-HER2 antibody-drug conjugate earlier this year, AstraZeneca and Daiichi Sankyo are riding high on the promise of their blooming partnership. Now a second ADC is showing promise in hard-to-treat breast cancer, and the companies have their eyes set on their only approved competitor in...

Click to view original post